Zevra Therapeutics (NASDAQ:KMPH – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, March 7th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.
Zevra Therapeutics Price Performance
The company has a 50-day simple moving average of $5.28 and a 200-day simple moving average of $5.37. Zevra Therapeutics has a 1 year low of $4.00 and a 1 year high of $6.92. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.10 and a current ratio of 10.10.
Get Zevra Therapeutics alerts:Analysts Set New Price Targets
KMPH has been the topic of several research analyst reports. StockNews.com raised Zevra Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 19th. Canaccord Genuity Group reduced their target price on shares of Zevra Therapeutics from $20.00 to $19.00 in a research note on Thursday, November 10th. Finally, Cantor Fitzgerald started coverage on shares of Zevra Therapeutics in a research note on Thursday, November 17th. They issued an "overweight" rating and a $20.00 target price for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.25.
Insider Activity at Zevra Therapeutics
In related news, CEO Richard W. Pascoe bought 9,500 shares of Zevra Therapeutics stock in a transaction that occurred on Friday, January 13th. The stock was acquired at an average price of $5.44 per share, for a total transaction of $51,680.00. Following the completion of the purchase, the chief executive officer now owns 19,973 shares in the company, valued at $108,653.12. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.10% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KMPH. UBS Group AG bought a new position in Zevra Therapeutics during the second quarter worth about $26,000. Verition Fund Management LLC bought a new position in Zevra Therapeutics during the fourth quarter worth about $46,000. Invesco Ltd. bought a new position in Zevra Therapeutics during the first quarter worth about $51,000. Kingsview Wealth Management LLC bought a new position in Zevra Therapeutics during the second quarter worth about $54,000. Finally, HRT Financial LP bought a new position in Zevra Therapeutics during the fourth quarter worth about $66,000. Institutional investors own 19.39% of the company's stock.
About Zevra Therapeutics
(Get Rating)
KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
Featured Articles
- Get a free copy of the StockNews.com research report on Zevra Therapeutics (KMPH)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.